To investigate E2F7 expression in lung adenocarcinoma and its link to immune infiltration. The mRNA expression levels of E2F7 in lung adenocarcinoma and adjacent non-cancerous tissues were assessed using data from TCGA. Additionally, the mRNA and protein expression levels of E2F7 in lung adenocarcinoma tissues were evaluated through RT-qPCR and immunohistochemistry. The association between E2F7 expression levels and the clinicopathological characteristics of patients was also examined. GO and KEGG analyses were conducted to investigate the genes co-expressed with E2F7 in lung adenocarcinoma within the TCGA database, and their relationships with immune cells and immune checkpoints were analyzed. E2F7 expression was significantly elevated in lung adenocarcinoma tissues compared to adjacent non-cancerous tissues. Furthermore, high E2F7 expression was significantly associated with poorer prognosis in lung adenocarcinoma patients. Genes co-expressed with E2F7 was predominantly enriched in pathways related to olfactory processes, chemical stimuli, and ligand-receptor interactions involved in neural activity. Furthermore, E2F7 expression is linked to various immune cell types and immune checkpoint pathways. E2F7 is significantly upregulated in lung adenocarcinoma tissues and is correlated with poor patient prognosis. Therefore, E2F7 may serve as a potential prognostic biomarker for patients with lung adenocarcinoma.
Gao et al. (Sun,) studied this question.